Related Experiment Video
Updated: Jan 7, 2026
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Raj Kumar1, Rudra Pal1, Sukhvir Kaur1
1Chitkara University School of Pharmacy, Chitkara University, Baddi, Himachal Pradesh, India.
Background:
Emerging research highlights a significant role of inflammation in the pathogenesis of Alzheimer's disease (AD). This study aims to analyze trends in clinical trials, focusing on the pivotal role of inflammation in drug development and early-stage AD, with the goal of identifying potential therapeutic targets for intervention.
Method:
This study analysis clinical reports on inflammatory markers in AD from the site ClinicalTrials.Gov with API on January 20, 2025, focusing on year-wise clinical study statuses. This study includes an analysis of recruiting, completed, terminated, withdrawn and observation trials to identify trends in the elimination and addition of studies. It also includes a summary of study categories, outcomes, biomarkers such as IL-6, TNF-α, and CSF cytokines with their advanced techniques which are used to analyze them.
Result:
A total of 134 studies were analyzed, among which before the 2015 very few number of studies were found. However, after 2015 there was increase in number of studies, which indicates a growing interest among the researchers in role of the inflammation in AD. Among all the studies, 44 (33%) studies were completed, and 25 (19%) are still recruiting, indicating ongoing interest. Completed studies report the changes in inflammatory biomarkers which are correlating with disease progression. Seven studies (5%) were terminated and four studies (3%) were withdrawn due to recruitment challenges and/or inconclusive results. Additionally, 30 studies (22%) focused on peripheral inflammatory biomarkers. Before 2015, studies are found and focused mainly on biomarkers like IL-6 and TNF-α. While after 2015, studies focus shift to advanced imaging, such as PET scans with TSPO ligands. Advanced imaging and transcriptomic techniques have enhanced the understanding the role of inflammation in microglial and astrocytic cells, which offers new diagnostic and therapeutic possibilities.
Conclusion:
Research highlights the growing role of inflammation in AD, with a shift towards advanced imaging and molecular techniques. Despite challenges in study design and recruitment, significant progress has been made. Future research should combine imaging, molecular markers, and clinical interventions to effectively address inflammation in AD.
Insights
Clinical trials investigating inflammation in Alzheimer's disease (AD) have surged since 2015, shifting towards advanced imaging and molecular techniques for better therapeutic targets.
Area of Science:
- Neuroscience
- Immunology
- Clinical Trials
Background:
- Emerging research implicates inflammation in Alzheimer's disease (AD) pathogenesis.
- Identifying therapeutic targets for early-stage AD is crucial.
Purpose of the Study:
- Analyze trends in clinical trials focusing on inflammation in AD drug development.
- Identify potential therapeutic targets for intervention in early-stage AD.
Main Methods:
- Analysis of clinical trial reports on inflammatory markers in AD from ClinicalTrials.gov.
- Examined year-wise study statuses (recruiting, completed, terminated, withdrawn).
- Summarized study categories, outcomes, and biomarkers (e.g., IL-6, TNF-α, CSF cytokines) with advanced analytical techniques.
Main Results:
- A notable increase in AD inflammation studies post-2015, indicating growing research interest.
- 44% of studies were completed, and 19% are recruiting, showing sustained research activity.
- A shift from traditional biomarkers (IL-6, TNF-α) to advanced imaging (PET scans) and molecular techniques post-2015.
Conclusions:
- Research confirms the increasing role of inflammation in AD, with a trend toward advanced imaging and molecular methods.
- Despite recruitment challenges, significant progress has been made in understanding inflammation's role in AD.
- Future research should integrate imaging, molecular markers, and clinical interventions for effective AD inflammation management.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
01:28Preclinical Development: Overview
01:11Clinical Trials: Overview
01:26Drug Discovery: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:10In Vitro Drug Release Testing: Overview, Development and Validation
01:25Drug Regulation